RxDoctor Payments Data

Sanil Nath, MD

Nephrology · Greenbelt, MDNPI 1548224934

Payments from drug & device makers

$653in general payments, 2019–2025

Across 20 payments — averaging $32.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$120
  • Fresenius USA Marketing, Inc.$102
  • Amgen$90
  • Mallinckrodt Enterprises LLC$75
  • Baxter Healthcare$66
  • AstraZeneca$48
  • plus $150 from 6 others

What the payments were for

  • Food & beverage$53682%
  • Education$11618%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$653 in reported general payments places this provider in the 50th percentile of 285 nephrology providers in Maryland.

See all nephrology providers in Maryland

Medicare billing

Part B allowed, 2024
$200,404
Medicare patients
308
Services billed
1,392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide25$56,078
JardianceEmpagliflozin76$45,535
FarxigaDapagliflozin Propanediol32$24,198
Sevelamer Carbonate32$7,277
JanuviaSitagliptin Phosphate11$6,343
ProsolParenteral Amino Acid 20% No.133$5,780
Calcium Acetate47$3,154
Labetalol Hcl35$938
Midodrine Hcl19$788
Amlodipine Besylate38$268
Lisinopril28$247
Allopurinol27$199
Losartan Potassium40$175
Nifedipine ErNifedipine13$175
Ibuprofen15$172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$102$56,07825 claims
AstraZenecaFarxiga$48$24,19832 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 285 nephrology providers in Maryland.

Other nephrology in Greenbelt

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →